Compare Southwest Airlines Co (LUV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Novavax Inc — how do they compare? Southwest Airlines Co trades at $48.24 (market cap $23.63B), while Novavax Inc trades at $8.08 (market cap $1.30B). The key difference: Southwest Airlines Co is far larger — about 18.2× Novavax Inc's market cap, and Southwest Airlines Co pays a 1.49% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| LUV | NVAX | |
|---|---|---|
Market Cap | $23.63B | $1.30B |
Sector | Industrials | Health |
52-Week High | $54.80 | $11.19 |
52-Week Low | $29.06 | $6.22 |
Enterprise Value | $26.70B | $800.50M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $48.69, up 1.27% today, with a neutral technical signal. The stock shows mixed earnings results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with Q2 2026 results pending. Revenue grew to $28.06B in 2025, though net income margin declined to 1.57%. Analyst consensus is a Buy with a $52.47 price target, indicating potential upside. Recent news highlights Q2 earnings anticipation and sector-wide factors like fuel costs and travel demand.
The outlook for LUV is cautiously optimistic, driven by resilient travel demand and cost management efforts. Key opportunities include earnings growth potential and favorable analyst targets. Risks involve fuel price volatility, competitive pressures, and execution challenges. Investors should weigh strong institutional interest against macroeconomic headwinds affecting the airline industry.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
